Hyperuricemia as predictor of in-hospital major adverse cardiac events in patients with acute myocardial infarction treated at Sanglah General Hospital, Denpasar-Bali
08/05/2017 Views : 180
Rani Paramitha Iswari Maliawan
Background: Even though hyperuricemia has been shown to have
roles in the formation of atherosclerosis and increasing incidence
of coronary heart disease, its role in predicting prognosis in
acute myocardial infarction (AMI) patients has not been widely studied.
Objective: This study aimed to investigate the role of hyperuricemia as
a predictor of in-hospital major adverse cardiac events (MACE) and to
determine the MACE-free survival difference between hyperuricemia
and normouricemia patients with AMI who were hospitalized at
Sanglah General Hospital.
Methods: Prospective cohort study with consecutive sampling was
conducted in AMI patients who were treated at Sanglah General Hospital
from November 2016 until February 2017. Uric acid level was measured
at the first admission and MACE during hospitalization was observed.
Results: Eighty-seven patients were involved in this study. We found
adjusted HR 1.875 (p=0.041; 95% CI 1.026-3.428) for the development
of in-hospital MACE. There was a significant difference (log-rank test
p=0.03) in MACE-free survival between hyperuricemia (mean survival
17.25 hours) and normouricemia (mean survival 43.389 hours) groups.
Conclusion: Hyperuricemia is an independent predictor of in-hospital
MACE in AMI patients hospitalized at Sanglah General Hospital.
Event-free survival of hyperuricemic patients is worse compared to
normouricemia patients during hospitalization.